{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:30:23Z","timestamp":1785879023613,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A recent database study and meta-analysis reported that adjunctive glucocorticoid therapy reduces mortality in patients with non-human immunodeficiency virus-associated (non-HIV)\n                      <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                      pneumonia (PCP), having hypoxemia. However, the optimal glucocorticoid dose remains unclear. Our study aimed to evaluate the effectiveness of pulse methylprednisolone compared with mild-to-moderate steroid doses in patients with non-HIV PCP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre retrospective cohort study included adults with non-HIV PCP receiving adjunctive steroids at three Japanese tertiary care hospitals from June 2006 to March 2021. Patients were categorised into pulse methylprednisolone and mild-to-moderate dose groups. Pulse methylprednisolone involved an initial intravenous infusion of 500\u20131000\u00a0mg methylprednisolone daily, while the mild-to-moderate dose was lower. Primary and secondary outcomes were 30-day and 180-day mortality from treatment initiation. Patient characteristics were adjusted using propensity score analysis with overlap weighting. Subgroup analysis focused on patients with respiratory failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 139 patients with non-HIV PCP: 55 in the pulse methylprednisolone group and 84 in the mild-to-moderate dose group. After adjusting for patient background, 30-day mortality (14.2% vs. 15.5%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.850) and 180-day mortality (33.5% vs. 27.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.516) did not differ significantly between groups. Subgroup analysis revealed no significant associations among patients with respiratory failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After adjusting for patient characteristics, no difference in prognosis was observed between pulse methylprednisolone and mild-to-moderate dose groups in patients with non-HIV PCP. A mild-to-moderate dose of adjunctive corticosteroid may suffice for treating non-HIV PCP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-024-10151-3","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T13:02:06Z","timestamp":1730552526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of pulse methylprednisolone in patients with non-human immunodeficiency virus pneumocystis pneumonia: a multicentre, retrospective registry-based cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yasuhiro","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Watari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"10151_CR1","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMra032588","volume":"350","author":"CF Thomas Jr","year":"2004","unstructured":"Thomas CF Jr, Limper AH. Pneumocystis Pneumonia. N Engl J Med. 2004;350:2487\u201398.","journal-title":"N Engl J Med"},{"key":"10151_CR2","doi-asserted-by":"publisher","unstructured":"Tasaka S, Tokuda H. PneumocJiroveciiovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012;18:793\u2013806. https:\/\/doi.org\/10.1007\/s10156-012-0453-0","DOI":"10.1007\/s10156-012-0453-0"},{"key":"10151_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1086\/339548","volume":"34","author":"KA Sepkowitz","year":"2002","unstructured":"Sepkowitz KA. Opportunistic infections in patients with and patients without acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002;34:1098\u2013107.","journal-title":"Clin Infect Dis"},{"key":"10151_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1099\/jmm.0.043984-0","volume":"61","author":"PV Coyle","year":"2012","unstructured":"Coyle PV, McCaughey C, Nager A, McKenna J, O\u2019Neill H, Feeney SA, et al. Rising incidence of Pneumocystis Jirovecii pneumonia suggests iatrogenic exposure of immune-compromised patients may be becoming a significant problem. J Med Microbiol. 2012;61:1009\u201315. https:\/\/doi.org\/10.1099\/jmm.0.043984-0","journal-title":"J Med Microbiol"},{"key":"10151_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","volume":"183","author":"AH Limper","year":"2011","unstructured":"Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96\u2013128. https:\/\/doi.org\/10.1164\/rccm.2008-740ST","journal-title":"Am J Respir Crit Care Med"},{"key":"10151_CR6","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkw158","volume":"71","author":"G Maschmeyer","year":"2016","unstructured":"Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P. ECIL guidelines for treatment of Pneumocystis Jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71:2405\u201313. https:\/\/doi.org\/10.1093\/jac\/dkw158","journal-title":"J Antimicrob Chemother"},{"key":"10151_CR7","unstructured":"Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/pneumocystis?view=full. Accessed 8 March 2024."},{"key":"10151_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7326\/0003-4819-113-1-14","volume":"113","author":"JS Montaner","year":"1990","unstructured":"Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;113:14\u201320. https:\/\/doi.org\/10.7326\/0003-4819-113-1-14","journal-title":"Ann Intern Med"},{"key":"10151_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJM199011223232103","volume":"323","author":"GS Boota. AM","year":"1990","unstructured":"Boota. AM GS, Fischl. MA BH, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990;323:1444\u201350.","journal-title":"N Engl J Med"},{"key":"10151_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJM199011223232104","volume":"323","author":"SA Bozzette","year":"1990","unstructured":"Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjunctive treatment with corticosteroids for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1990;323:1451\u20137. https:\/\/doi.org\/10.1056\/NEJM199011223232104","journal-title":"N Engl J Med"},{"key":"10151_CR11","doi-asserted-by":"publisher","first-page":"CD006150","DOI":"10.1002\/14651858.CD006150.pub2","volume":"2015","author":"H Ewald","year":"2015","unstructured":"Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis Jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015;2015:CD006150. https:\/\/doi.org\/10.1002\/14651858.CD006150.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"10151_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1086\/598651","volume":"29","author":"C Delclaux","year":"1999","unstructured":"Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F, Brochard L, et al. Corticosteroids as adjunctive therapy for severe pneumocystis carinii pneumonia in non-HIV. Clin Infect Dis. 1999;29:670\u20132.","journal-title":"Clin Infect Dis"},{"key":"10151_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijid.2018.12.001","volume":"79","author":"N Inoue","year":"2019","unstructured":"Inoue N, Fushimi K. Adjunctive corticosteroids decreased the risk of mortality of non-HIV Pneumocystis Pneumonia. Int J Infect Dis. 2019;79:109\u201315. https:\/\/doi.org\/10.1016\/j.ijid.2018.12.001","journal-title":"Int J Infect Dis"},{"key":"10151_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13613-020-00649-9","volume":"10","author":"L Ding","year":"2020","unstructured":"Ding L, Huang H, Wang H, He H. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care. 2020;10:34. https:\/\/doi.org\/10.1186\/s13613-020-00649-9","journal-title":"Ann Intensive Care"},{"key":"10151_CR15","doi-asserted-by":"publisher","first-page":"59729","DOI":"10.18632\/oncotarget.19927","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Su L, Jiang SJ, Qu H. Risk factors for mortality from Pneumocystis carinii pneumonia (PCP) in non-HIV patients a meta-analysis. Oncotarget. 2017;8:59729\u201339.","journal-title":"Oncotarget"},{"key":"10151_CR16","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1093\/cid\/ciaa1805","volume":"72","author":"K Lagrou","year":"2021","unstructured":"Lagrou K, Chen S, Masur H, Viscoli C, Decker CF, Pagano L, et al. Pneumocystis Jirovecii Disease: basis for the revised EORTC\/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus. Clin Infect Dis. 2021;72:S114\u201320. https:\/\/doi.org\/10.1093\/cid\/ciaa1805","journal-title":"Clin Infect Dis"},{"key":"10151_CR17","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1056\/NEJMc070728","volume":"1","author":"M Harigai","year":"2007","unstructured":"Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;1:1874\u20136.","journal-title":"N Engl J Med"},{"key":"10151_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jmii.2017.07.007","volume":"51","author":"K Nakashima","year":"2018","unstructured":"Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, et al. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study. J Microbiol Immunol Infect. 2018;51:810\u201320. https:\/\/doi.org\/10.1016\/j.jmii.2017.07.007","journal-title":"J Microbiol Immunol Infect"},{"key":"10151_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.chest.2023.08.009","volume":"165","author":"T Nagai","year":"2024","unstructured":"Nagai T, Matsui H, Fujioka H, Homma Y, Otsuki A, Ito H, et al. Low-dose vs conventional-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis Pneumonia in patients not infected with HIV: a Multicenter, Retrospective Observational Cohort Study. Chest. 2024;165:58\u201367. https:\/\/doi.org\/10.1016\/j.chest.2023.08.009","journal-title":"Chest"},{"key":"10151_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cmi.2020.05.024","volume":"26","author":"O Del Corpo","year":"2020","unstructured":"Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1\u20133)-beta-D-glucan for Pneumocystis Jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26:1137\u201343. https:\/\/doi.org\/10.1016\/j.cmi.2020.05.024","journal-title":"Clin Microbiol Infect"},{"key":"10151_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1186\/s12879-021-06895-x","volume":"21","author":"J Taniguchi","year":"2021","unstructured":"Taniguchi J, Nakashima K, Matsui H, Watari T, Otsuki A, Ito H, et al. Low cut-off value of serum (1,3)-beta-D-glucan for the diagnosis of Pneumocystis pneumonia in non-HIV patients: a retrospective cohort study. BMC Infect Dis. 2021;21:1200. https:\/\/doi.org\/10.1186\/s12879-021-06895-x","journal-title":"BMC Infect Dis"},{"key":"10151_CR22","doi-asserted-by":"publisher","first-page":"ofab545","DOI":"10.1093\/ofid\/ofab545","volume":"8","author":"EG McDonald","year":"2021","unstructured":"McDonald EG, Butler-Laporte G, Del Corpo O, Hsu JM, Lawandi A, Senecal J, et al. On the treatment of Pneumocystis Jirovecii Pneumonia: current practice based on outdated evidence. Open Forum Infect Dis. 2021;8:ofab545. https:\/\/doi.org\/10.1093\/ofid\/ofab545","journal-title":"Open Forum Infect Dis"},{"key":"10151_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s15010-015-0851-1","volume":"44","author":"D Creemers-Schild","year":"2016","unstructured":"Creemers-Schild D, Kroon FP, Kuijper EJ, de Boer MG. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study. Infection. 2016;44:291\u20139. https:\/\/doi.org\/10.1007\/s15010-015-0851-1","journal-title":"Infection"},{"key":"10151_CR24","doi-asserted-by":"publisher","first-page":"e1252","DOI":"10.1093\/cid\/ciac386","volume":"76","author":"H Hammarstrom","year":"2023","unstructured":"Hammarstrom H, Krifors A, Athlin S, Friman V, Golestani K, Hallgren A, et al. Treatment with reduced-dose trimethoprim-sulfamethoxazole is effective in mild to moderate pneumocystis jirovecii pneumonia in patients with hematologic malignancies. Clin Infect Dis. 2023;76:e1252\u201360. https:\/\/doi.org\/10.1093\/cid\/ciac386","journal-title":"Clin Infect Dis"},{"key":"10151_CR25","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a Randomized Clinical Trial. JAMA. 2020;323:2417\u20138. https:\/\/doi.org\/10.1001\/jama.2020.7819","journal-title":"JAMA"},{"key":"10151_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","volume":"56","author":"S Homma","year":"2018","unstructured":"Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018;56:268\u201391. https:\/\/doi.org\/10.1016\/j.resinv.2018.03.003","journal-title":"Respir Investig"},{"key":"10151_CR27","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/resp.13365","volume":"23","author":"Y Yamano","year":"2018","unstructured":"Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology. 2018;23:1041\u20138. https:\/\/doi.org\/10.1111\/resp.13365","journal-title":"Respirology"},{"key":"10151_CR28","doi-asserted-by":"publisher","first-page":"h6819","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819. https:\/\/doi.org\/10.1136\/bmj.h6819","journal-title":"BMJ"},{"key":"10151_CR29","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"key":"10151_CR30","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJM199011223232131","volume":"323","author":"National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia","year":"1990","unstructured":"National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1500.","journal-title":"N Engl J Med"},{"key":"10151_CR31","unstructured":"Guidelines for the Prevention. and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/pneumocystis?view=full Accessed 24 Sepember 2024."},{"key":"10151_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1183\/20734735.001415","volume":"11","author":"JA Collins","year":"2015","unstructured":"Collins JA, Rudenski A, Gibson J, Howard L, O\u2019Driscoll R. Relating oxygen partial pressure, saturation and content: the haemoglobin-oxygen dissociation curve. Breathe (Sheff). 2015;11:194\u2013201. https:\/\/doi.org\/10.1183\/20734735.001415","journal-title":"Breathe (Sheff)"},{"key":"10151_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2024.6096","volume":"332","author":"R Pirracchio","year":"2024","unstructured":"Pirracchio R, Venkatesh B, Legrand M. Low-dose corticosteroids for critically ill adults with severe pulmonary infections: a review. JAMA. 2024;332:318\u201328. https:\/\/doi.org\/10.1001\/jama.2024.6096","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10151-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10151-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10151-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T13:02:10Z","timestamp":1730552530000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10151-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10151"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10151-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4781746\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the research ethics committee at each participating centre: the Research Ethics Committee of Kameda Medical Center (#21-069-230801), the Institutional Review Board and Ethics Committee of Seirei Hamamatsu General Hospital (#3584), and the Ethics Committee of Seirei Mikatahara General Hospital (#21\u201358). As this was a retrospective study and patient data were anonymised, the requirement for written informed consent was waived. This was also approved by the ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have completed the STROBE reporting checklist (\n                      \n                      ) (submitted as a supplementary file).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Reporting Checklist"}}],"article-number":"1233"}}